Online Courses

Release date: March 13, 2024
Expiration date: March 13, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity CE, LLC.
This CE activity for AANP credit is jointly provided by Global Education Group and Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by educational grants from Sanofi and Regeneron Pharmaceuticals.

PROGRAM OVERVIEW

Uncontrolled atopic dermatitis (AD) can have dire, lifelong consequences for children and their families. However, medical science has developed several treatments that target the molecular drivers of this immuno-inflammatory skin disease that has negative effects on overall health and quality of life. Join AD expert Dr. Peter Lio for this on-demand video activity about systemic therapeutic options for infants, children, and adolescents who are affected by moderate-to-severe AD.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of pediatric dermatologists, dermatologists, pediatricians, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage pediatric patients with atopic dermatitis.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Characterize the extracutaneous consequences of uncontrolled moderate-to-severe atopic dermatitis (AD) on patients and parents/caregivers
• Delineate the immuno-inflammatory molecular catalysts that underly moderate or severe manifestations of pediatric AD
• Describe how to integrate systemic therapeutic options for infants, children, and adolescents who are affected by moderate-to-severe AD

FACULTY

Peter Lio, MD, FAAD Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai Clinical Assistant Professor of Dermatology & Pediatrics Northwestern University Feinberg School of Medicine Founding Director, Chicago Integrative Eczema Center Founding Partner, Medical Dermatology Associates of Chicago Chicago, Illinois

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC and Global Education Group requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:

Peter Lio, MD, FAAD
Advisory Boards: AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Boston Skin Science (KPAway), Burt’s Bees, Castle Biosciences, Concerto Biosciences, Dermavant, Dermira, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosciences, Kimberly-Clark, LEO, Level Ex, Lipidor AB, L’Oréal, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, SkinFix, Theraplex, Unilever, Verrica, YobeeCare
Patent Holder: Theraplex AIM (patent pending)
Research: AbbVie, AOBiome, Regeneron/Sanofi Genzyme
Speaker: AbbVie, Eli Lilly, Galderma, Incyte, LEO, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme
Stock Options: Altus Labs, Boston Skin Science (KPAway), Concerto Biosciences, LearnSkin,
Micreos, YobeeCare

The Integrity CE, LLC and Global Education Group planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME/CE credit for this activity. During the period of March 13, 2024 through March 13, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 67% or better and a completed activity evaluation form.

ACCREDITATION

Physician Continuing Education

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity CE, LLC. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hours (which includes 0.0 hour(s) of pharmacology).

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

For information about AANP accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: April 8, 2024
Expiration date: April 8, 2025
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Sanofi.

PROGRAM OVERVIEW

Every 5 minutes, someone is diagnosed with multiple sclerosis (MS), according to the Multiple Sclerosis International Federation’s Atlas of MS. Along with 85% of other newly diagnosed patients with MS, they will be diagnosed with relapsing-remitting MS (RRMS), one of the four MS subtypes.

In 2024, five emerging Bruton’s tyrosine kinase (BTK) inhibitors are undergoing late-phase clinical investigation for MS, but most clinicians are likely unaware of their place in the development pipeline and the clinical data regarding their use in MS. This Deep Dive activity into recently published or released data about BTK inhibitors in MS will convey critical information to neurologists and other clinicians about this innovative approach to MS management.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of neurologists, primary care physicians, nurse practitioners, physician assistants, and other clinicians who manage patients with MS.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Identify the role of BTK as a therapeutic target in the immunopathogenesis of MS
• Explain the mechanism of action of BTK inhibitors when used for MS
• Outline ideas for incorporating BTK inhibitors (when FDA approved) into therapeutic options for MS based on new and emerging efficacy and safety findings from clinical trials

FACULTY

Daniel S. Reich, MD, PhD Senior Investigator and Chief Translational Neuroradiology Section National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health (NIH), USA​

He appears here in his private capacity, as an approved Outside Activity, and the views and opinions here do not represent those of NINDS or NIH.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Daniel S. Reich, MD, PhD
NIH Cooperative Research and Development Agreements: Abata Therapeutics, Sanofi

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period April 8, 2024 through April 8, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: March 2024
Expiration date: March 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from ALK-Abello, Inc.

PROGRAM OVERVIEW

Allergic rhinitis with or without conjunctivitis (AR/C) in children and adolescents is a commonly misunderstood, misdiagnosed, and mistreated condition. AR/C exerts a significant effect on quality of life and has deleterious effects on sleep, academic performance, family functioning, and involvement in outdoor activities. Fortunately, there have been advances in the diagnosis and treatment of AR/C that support improved diagnosis and care of patients with inadequate relief from symptom-relieving therapies, including broadly available specific immunoglobulin E (lgE) tests, advances in understanding of immune mechanisms, and newer allergen immunotherapies including oral tablet immunotherapy.

This program will review these important updates to provide clinicians with the knowledge and skills to provide care to children and adolescents with AR/C that is aligned with the latest evidence and best practices.

TARGET AUDIENCE

This educational activity has been designed for pediatricians, pediatric nurse practitioners, and pediatric physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Discuss the burden of symptoms of AR/C and the associated impacts on quality of life in children and adolescents
• Implement strategies for the early diagnosis and optimal assessment of AR/C in the pediatric setting
• Describe the role of allergy immunotherapy in the management of patients with AR/C
• Utilize available therapies to achieve optimal management of pediatric patients with AR/C

FACULTY

Michelle Yasharpour, MD Allergy and Immunology Cedars Sinai Medical Center Beverly Hills, California

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Michelle Yasharpour, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of March, 2024 through March, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 65% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: March 15, 2024
Expiration date: September 15, 2024
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

PROGRAM OVERVIEW

EoE is an immuno-inflammatory disease that affects people of all age groups (including children) and is often triggered by certain foods or aeroallergen microbes. The prevalence of EoE has increased over the past few decades, and few clinicians — including specialists in gastroenterology — are able to recognize the signs and symptoms of this disease. Patients with EoE are often misdiagnosed or go without a correct diagnosis (and appropriate treatment) for several years. What is known to be the appropriate treatment has historically comprised a wide variety of dietary interventions that can be difficult to adhere to and off-label pharmacologics that have mixed efficacy. Since the approval of dupilumab, the first drug ever to be given an EoE indication, treatment options have expanded, offering a new landscape for gastroenterologists, allergists, and other clinicians who manage patients with EoE by giving them a new way to personalize treatment approaches for both their adult and pediatric patients.

Whether you work in primary care, pediatrics, or in gastroenterology, follow along with Drs. Chang and Chehade to improve the diagnosis and management of patients with EoE. This self-paced course will allow for a unique learning path based on your current knowledge and skill level and enhance understanding of EoE disease burden and clinical indicators of EoE, improve rates of referral, and assist in the creation of more individualized treatment plans.

TARGET AUDIENCE

This activity addresses the needs of gastroenterologists, pediatric gastroenterologists, specialty advanced practice providers, pediatricians and pediatric nurse practitioners, and internal medicine clinicians.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Identify signs, symptoms, and clinical indicators of EoE to facilitate referral for specialist evaluation or earlier diagnosis
• Assess the disease burden of EoE and the weight of its effect on physical and psychological quality of life
• Employ strategies for individualized treatment and monitoring of treatment response
• Incorporate new or emerging EoE treatments based on efficacy and safety findings from clinical trials

FACULTY

	Joy W. Chang, MD MS Assistant Professor of Internal Medicine Division of Gastroenterology University of Michigan Ann Arbor, Michigan
	Mirna Chehade, MD, MPH, AGAF, FAAAAI Professor of Pediatrics and Medicine Founding Director, Mount Sinai Center for Eosinophilic Disorders Icahn School of Medicine at Mount Sinai New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Mirna Chehade, MD, MPH
Consultant: Adare/Ellodi, Allakos, AstraZeneca, Bristol Myers SquibbNexstone Immunology, Phathom, Recludix Pharma, Regeneron, Sanofi, Shire/Takeda,
Research Funding: Adare/Ellodi, Allakos, AstraZeneca Regeneron, Bristol Myers Squibb, Danone, Shire/Takeda

Joy W. Chang, MD MS
Consultant: Sanofi-Regeneron
Speaker: Sanofi-Regeneron

Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of March 15, 2024 through September 15, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 75% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc. you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: February 28, 2024
Expiration date: February 28, 2025
Estimated time to complete activity: 75 minutes

PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity CE, LLC.
This CE activity for AANP credit is jointly provided by Global Education Group and Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from ALK-Abello, Inc.

PROGRAM OVERVIEW

Allergic rhinitis usually presents in early childhood and is caused by an immunoglobulin E (IgE)-mediated reaction to various indoor and outdoor allergens. In this video activity, Dr. Michael Blaiss will discuss the burden of symptoms of allergic rhinitis/rhinoconjunctivitis (AR/C), how to implement strategies for early diagnosis, and the role of allergy immunotherapy in the management of patients with AR/C.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of pediatric allergists, allergists, pediatricians, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage pediatric patients with allergic rhinitis.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Discuss the burden of symptoms of AR/C and the associated impacts on quality of life in children and adolescents
• Discuss how to implement strategies for the early diagnosis and optimal assessment of AR/C in the pediatric setting
• Describe the role of allergy immunotherapy in the management of patients with AR/C
• Discuss how to utilize available therapies to achieve optimal management of pediatric patients with AR/C

FACULTY

Michael S. Blaiss, MD, FAAAAI, FACAAI Clinical Professor of Pediatrics Medical College of Georgia at Augusta University Augusta, Georgia

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:

Michael S. Blaiss, MD, FAAAAI, FACAAI
Consulting Fees: ALK-Abello, Inc., AnaptysBio, AstraZeneca, Bellus, GlaxoSmithKline, Hippo Dx, Lanier Biotherapeutics, Merck, Prollergy, Regeneron, Sanofi
Speaker’s Bureaus: ALK-Abello Inc., Merck, Regeneron, Sanofi

The Integrity CE, LLC and Global Education Group planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME/CE credit for this activity. During the period of February 28, 2024 through February 28, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 60% or better and a completed activity evaluation form.

ACCREDITATION

Physician Continuing Education

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity CE, LLC. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.25 contact hours (which includes 0.125 hour(s) of pharmacology).

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

For information about AANP approval of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: February 15, 2024
Expiration date: August 15, 2024
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

PROGRAM OVERVIEW

Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. An increased understanding of the pathophysiology of COPD, particularly the eosinophilic phenotype, has shown that the cytokines IL-4, IL-5, and IL-13 play a critical part in the inflammatory process. IL-33 also appears to be involved in this process. The discovery of these cytokines and the role they have in T2 inflammation points to potential therapeutic targets, and predictive biomarkers for treatment response and disease progression. Three newly approved therapies for asthma that target IL-4, IL-5, and/or IL-13 (mepolizumab, benralizumab, and dupilumab) are now in trials for COPD, while iItepekimab is under investigation for both asthma and COPD. Available evidence to date shows the promise for a biologic to potentially be approved and available for the treatment of COPD in the near future. In this activity, Drs. Surya Bhatt and Nicola Hanania will engage in a dynamic discussion and walk you through a series of interactive case-based decision points to help you learn more about T2 inflammation in COPD and how to best manage these patients given currently available data.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of US pulmonologists, specialty advanced practice providers (APPs), and internal medicine clinicians.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Describe the pathologic evidence for T2 inflammation in COPD and potential treatment targets
• Identify available biomarkers that signal T2 inflammation in COPD and may predict disease progression or treatment response
• Review available clinical data supporting the use of targeted biologics in the management of patients with COPD
• Develop management plans for patients with COPD based on individual patient characteristics

FACULTY

	Surya P. Bhatt, MD Medical Director Pulmonary Function and Exercise Physiology Lab University of Alabama–Birmingham Birmingham, Alabama
	Nicola Alexander Hanania, MD Professor of Medicine Director, Airways Clinical Research Center Baylor College of Medicine Houston, Texas

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Surya P. Bhatt, MD
Advisory Board: Boehringer Ingelheim, GSK, Regeneron, Sanofi
Consulting: Boehringer Ingelheim, Sanofi
Research Support: Nuvaira, Sanofi, Genentech

Nicola Alexander Hanania, MD
Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Sanofi, Teva
Research Support: AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Novartis, Sanofi, Teva
Speaker: Sanofi

Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of February 15, 2024 through August 15, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 65% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc. you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: February 5, 2024
Expiration date: August 5, 2024
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

PROGRAM OVERVIEW

Although immunotherapy has dramatically expanded the treatment landscape for a range of advanced cancers, there are several subtypes, including certain breast and lung cancers, that remain resistant to standard treatments and for which treatment options are limited. As a result, many patients continue to experience declining response rates, disease control, and quality of life. Nevertheless, efforts to identify novel approaches for addressing these significant unmet needs are ongoing. One approach that has shown a great deal of promise and has garnered significant attention recently is the use of antibody-drug conjugates (ADCs) that target Trop-2, a transmembrane glycoprotein that is upregulated in many cancers. By taking advantage of monoclonal antibodies selective for Trop-2, these agents enable the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells. There is currently only one Trop-2 ADC that has been approved by the FDA for TNBC and HR+/HER2- BC. However, evidence continues to emerge in support of the use of multiple Trop-2 ADCs in not only these cancers, but others as well.

Join Drs. Jason Porter and Lee Schwartzberg as they dive deeper into the most relevant data on Trop-2 ADCs and help clinicians incorporate Trop-2-targeted ADCs into evidence-based treatment plans for patients with TNBC, HR+/HER2- BC, and NSCLC.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of community oncologists and advanced practice providers involved in the care of patients with breast or lung cancers.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Describe the rationale for Trop-2 ADCs for the treatment of breast and lung cancer
• Review current and emerging evidence supporting the use of Trop-2 ADCs for the treatment of TNBC, HR+/HER2- BC, and NSCLC
• Design evidence-based plans for the treatment of TNBC, HR+/HER2- BC, and NSCLC employing Trop-2 ADCs

FACULTY

	Jason Porter, MD Medical Oncologist/Hematologist West Cancer Center and Research Institute Memphis, Tennessee
	Lee Schwartzberg, MD, FACP Professor of Clinical Medicine University of Nevada – Reno Chief, Medical Oncology/Hematology William N. Pennington Cancer Institute at Renown Health Reno, Nevada

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Jason Porter, MD
Consultant: Amgen, Bristol Myers Squibb, G1 Therapeutics Inc., Jazz, Merck, Mirati, Novartis, Regeneron Pharmaceuticals, Inc.
Speaker: Amgen, Bristol Myers Squibb, G1 Therapeutics Inc., Jazz, Merck, Mirati, Novartis, Regeneron Pharmaceuticals, Inc.

Lee Schwartzberg, MD, FACP
Consultant: AstraZeneca, Daiichi Sankyo, Genentech, Napo, Novartis, Seagen
Speaker: AstraZeneca, Daiichi Sankyo, Merck, Novartis, Pfizer, Seagen

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of February 5, 2024 through August 5, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 60% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: January 15, 2024
Expiration date: April 15, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This educational activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

PROGRAM OVERVIEW

Stage III non-small cell lung cancer (NSCLC) is a heterogenous disease that is typically treated with multimodal therapeutic approaches, which may include systemic therapies, radiotherapy, and surgery. Individualizing treatment strategies for patients with stage III NSCLC requires accurate clinical and pathological staging. The treatment journey of patients with stage III NSCLC has evolved rapidly over the last few years with improved staging approaches and approval of consolidation immunotherapy following concurrent chemoradiotherapy (cCRT).

Pretreatment multidisciplinary team discussion is crucial in defining the most optimal treatment approach for each patient. This activity will feature Dr. Ticiana Leal sharing her thoughts on the implications for cCRT and consolidation with durvalumab in the perioperative treatment paradigm.

TARGET AUDIENCE

This educational activity was developed to meet the professional needs of medical, surgical, and radiation oncologists, along with other healthcare providers involved in the treatment and management of patients with lung cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Evaluate the efficacy and safety data of current and emerging therapeutic approaches for patients with unresectable stage III NSCLC

FACULTY CHAIR

Ticiana Leal, MD Associate Professor Department of Hematology/Oncology Director, Thoracic Medical Oncology Program Winship Cancer Institute Emory University Atlanta, Georgia

FACULTY DISCUSSANTS

	Aakash Desai, MD Assistant Professor University of Alabama at Birmingham Birmingham, Alabama
	Kristin A. Higgins, MD Professor and Vice Chair of Clinical Research Department of Radiation Oncology Winship Cancer Institute Emory University Atlanta, Georgia

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Aakash Desai, MD
Consultant: Amgen, AstraZeneca, Foundation Medicine, Sanofi

Kristin A. Higgins, MD
Advisory Boards: AstraZeneca, Janssen Pharmaceuticals
Consultant: Picture Health
Funded Research: Jazz Pharmaceuticals

Ticiana Leal, MD, does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of January 15, 2024 through April 15, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: January 11, 2024
Expiration date: January 11, 2025
Estimated time to complete activity: 30 minutes

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

PROGRAM OVERVIEW

This activity will provide context and insight on the latest data in multiple myeloma and precursor conditions released at the recent meeting in San Diego, led by expert faculty, Dr. Ola Landgren and Dr. Saad Usmani. The following abstracts will be covered:

• Relapsed/Refractory Multiple Myeloma (RRMM)
  • Oral Abstract 1021 – The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)
  • Oral Abstract 542 – Real-World Results: Treatment Patterns and Clinical Outcomes Among Triple-Class– and BCMA-Exposed Multiple Myeloma
  • Oral Abstract 91 – Real-World Outcomes With Teclistamab for Heavily-Pretreated Relapsed-Refractory Multiple Myeloma
  • Oral Abstract 1023 – Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients
  • Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients
• Newly-Diagnosed Multiple Myeloma (NDMM)
  • Oral Abstract 210 – Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study
  • Oral Abstract LBA-1 – PERSEUS  – Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
  • Oral Abstract 4 – Iskia esults of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

TARGET AUDIENCE

This educational activity was designed for community-based medical oncologists and hematologists, as well as other healthcare providers that treat and manage patients with hematologic malignancies.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options
• Identify patients that could potentially benefit from referral to a clinical trial

FACULTY

	Ola Landgren, MD, PhD Chief of Myeloma Professor of Medicine Director, Slyvester Myeloma Institute University of Miami Miami, Florida
	Saad Usmani, MD, MBA, FACP, FRCP Chief of Myeloma Service Member, Memorial Sloan Kettering Cancer Center Attending Physician, Myeloma, Cellular Therapy and Adult BMT Professor, Weill Cornell Medical College – Cornell University New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Ola Landgren, MD, PhD
Advisory Boards: Adaptive Biotech, Amgen, Bristol Myers Squibb, Janssen, Pfizer
Grant Support: Amgen, Janssen, Karyopharm, Takeda

Saad Usmani, MD, MBA, FACP, FRCP
Advisory Boards: AbbVie, Amgen, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio
Consultant: AbbVie, Amgen, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio
Research Funding: Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of January 11, 2024 through January 11, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 72% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: January 8, 2024
Expiration date: January 8, 2025
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

PROGRAM OVERVIEW

Prurigo nodularis (PN) is a dermatologic disease that starts at a deep, neuro-immune molecular level and nothing applied to or done to the top of the skin will ever bring relief. The only thing that will work to tame the itch are targeted treatments that address the underlying type 2 immuno-inflammatory molecular drivers of this disease. Fortunately, patients with PN now have an FDA-approved treatment option that does just that, and other treatments in late-phase clinical development may be close behind. Join our expert faculty as they explore PN and its new and emerging treatment options.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of dermatologists as well as nurse practitioners and physician assistants involved in the management of patients with PN.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Characterize the burden of disease imposed by PN, including unbearable itch, diminished quality of life, and psychological distress
• Describe the pathogenesis and pathophysiology of PN
• Discuss evidence-based management strategies when assessing and treating PN
• Integrate new and emerging therapies into treatment regimens for appropriately selected patients with PN

FACULTY CHAIR

Shawn G. Kwatra, MD  Associate Professor of Dermatology Department of Dermatology Director, Johns Hopkins Itch Center Johns Hopkins University School of Medicine Baltimore, Maryland

FACULTY

Sarina Elmariah, MD, PhD, MPH Associate Professor, Dermatology Director, UCSF Center for Itch and Neurosensory Disorders University of California San Francisco San Francisco, California

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Sarina Elmariah, MD, PhD, MPH
Advisory Board: Bellus Health, Galderma, Lilly, Pfizer, Sanofi-Regeneron, Trevi Therapeutics
Stocks: New Frontier Bio

Shawn G. Kwatra, MD
Consultant: AbbVie, Acrutis Biotherapeutics, Aslan Pharmaceuticals, Castle Bioscience, Celldex Therapeutics, Novartis
Investigator: Incyte, Pfizer, Regeneron, Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of January 8, 2024, through January 8, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 1, 2023
Expiration date: March 31, 2024
Estimated time to complete activity: 30 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

PROGRAM OVERVIEW

Treatment with biologic therapy as compared with maintenance corticosteroids (oral or high-dose inhaled) has consistently been shown to reduce disease burden among a wide range of individuals with moderate-to-severe asthma. Nevertheless, a significant subset of patients treated with biologics continues to experience poor asthma control and a high burden of disease, raising important questions regarding how to optimize the use of available therapies. Join our esteemed clinician faculty as they discuss the selection of appropriate initial biologic therapy for patients with moderate-to-severe asthma to improve health outcomes.

TARGET AUDIENCE

This educational activity has been designed for US allergists, pulmonologists, advanced practice providers in allergy and pulmonary settings, and internal medicine clinicians.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Select the most appropriate biologic for patients with uncontrolled asthma based on comprehensive assessment of individual characteristics

FACULTY CO-CHAIRS

	Linda B. Ford, MD, FAAAAI, FACAAI, AE-C Clinical Assistant Professor Department of Pediatrics University of Nebraska Medical Center President and CEO The Asthma & Allergy Center, PC Omaha, Nebraska
	Reynold A. Panettieri, Jr., MD Vice Chancellor, Translational Medicine and Science Director, Rutgers Institute for Translational Medicine and Science Professor of Medicine, Rutgers University Emeritus Professor of Medicine, University of Pennsylvania New Brunswick, New Jersey

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Linda B. Ford, MD, FAAAAI, FACAAI, AE-C
Independent Contractor: Allergy Therapeutics, AstraZeneca, Bellus, Chiesi, Enanta, Genentech, Koneksa, Regeneron, Sanofi, Suzhou

Reynold A. Panettieri, Jr., MD
Advisor: Praesidia Biotherapies Inc.
Advisory Board: AstraZeneca, Genentech, RIFM
Consultant: AstraZeneca, RIFM, TEVA
Research Grants: ACTIV-1, AgoMab, AstraZeneca, Janssen, Medimmune, RIFM, TEVA, Vault Health
Speaker: AstraZeneca, Merck & Co., Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 1, 2023 through March 31, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 1, 2023
Expiration date: March 31, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

PROGRAM OVERVIEW

Treatment with biologic therapy as compared with maintenance corticosteroids (oral or high-dose inhaled) has consistently been shown to reduce disease burden among a wide range of individuals with moderate-to-severe asthma. Nevertheless, a significant subset of patients treated with biologics continue to experience poor asthma control and a high burden of disease, raising important questions regarding how to optimize the use of available therapies. Join our esteemed clinician faculty as they discuss evaluating biologic therapy responses for patients with moderate-to-severe asthma to improve health outcomes.

TARGET AUDIENCE

This educational activity has been designed for US allergists, pulmonologists, advanced practice providers in allergy and pulmonary settings, and internal medicine clinicians.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Describe current recommendations for assessment of biologic therapy after initiation and factors that may predispose patients to biologic stopping or switching in the first year of therapy

FACULTY CO-CHAIRS

	Linda B. Ford, MD, FAAAAI, FACAAI, AE-C Clinical Assistant Professor Department of Pediatrics University of Nebraska Medical Center President and CEO The Asthma & Allergy Center, PC Omaha, Nebraska
	Reynold A. Panettieri, Jr., MD Vice Chancellor, Translational Medicine and Science Director, Rutgers Institute for Translational Medicine and Science Professor of Medicine, Rutgers University Emeritus Professor of Medicine, University of Pennsylvania New Brunswick, New Jersey

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Linda B. Ford, MD, FAAAAI, FACAAI, AE-C
Independent Contractor: Allergy Therapeutics, AstraZeneca, Bellus, Chiesi, Enanta, Genentech, Koneksa, Regeneron, Sanofi, Suzhou

Reynold A. Panettieri, Jr., MD
Advisor: Praesidia Biotherapies Inc.
Advisory Board: AstraZeneca, Genentech, RIFM
Consultant: AstraZeneca, RIFM, TEVA
Research Grants: ACTIV-1, AgoMab, AstraZeneca, Janssen, Medimmune, RIFM, TEVA, Vault Health
Speaker: AstraZeneca, Merck & Co., Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 1, 2023 through March 31, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 1, 2023
Expiration date: March 31, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

PROGRAM OVERVIEW

Treatment with biologic therapy as compared with maintenance corticosteroids (oral or high-dose inhaled) has consistently been shown to reduce disease burden among a wide range of individuals with moderate-to-severe asthma. Nevertheless, a significant subset of patients treated with biologics continue to experience poor asthma control and a high burden of disease, raising important questions regarding how to optimize the use of available therapies. Join our esteemed clinician faculty as they discuss long-term biologic treatment data for patients with moderate-to-severe asthma.

TARGET AUDIENCE

This educational activity has been designed for US allergists, pulmonologists, advanced practice providers in allergy and pulmonary settings, and internal medicine clinicians.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Review long-term efficacy and safety data of available biologics reported in real-world and open-label extension trials

FACULTY CO-CHAIRS

	Linda B. Ford, MD, FAAAAI, FACAAI, AE-C Clinical Assistant Professor Department of Pediatrics University of Nebraska Medical Center President and CEO The Asthma & Allergy Center, PC Omaha, Nebraska
	Reynold A. Panettieri, Jr., MD Vice Chancellor, Translational Medicine and Science Director, Rutgers Institute for Translational Medicine and Science Professor of Medicine, Rutgers University Emeritus Professor of Medicine, University of Pennsylvania New Brunswick, New Jersey

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Linda B. Ford, MD, FAAAAI, FACAAI, AE-C
Independent Contractor: Allergy Therapeutics, AstraZeneca, Bellus, Chiesi, Enanta, Genentech, Koneksa, Regeneron, Sanofi, Suzhou

Reynold A. Panettieri, Jr., MD
Advisor: Praesidia Biotherapies Inc.
Advisory Board: AstraZeneca, Genentech, RIFM
Consultant: AstraZeneca, RIFM, TEVA
Research Grants: ACTIV-1, AgoMab, AstraZeneca, Janssen, Medimmune, RIFM, TEVA, Vault Health
Speaker: AstraZeneca, Merck & Co., Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 1, 2023 through March 31, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: January 9, 2024
Expiration date: January 9, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharpe & Dohme, LLC.

PROGRAM OVERVIEW

This activity will provide context and insight on the latest data in breast cancer released at the recent meeting in San Antonio, led by expert faculty. The following abstracts will be covered:

• CAPItello-291
• TROPION-Breast01
• Real-world Outcomes With ADCs for HER2-low Metastatic Breast Cancer
• KEYNOTE-756
• KEYNOTE-522
• neoMono
• Neo-N
• ALEXANDRA/IMpassion030
• APTneo
• KATHERINE
• HER2CLIMB-02
• HERB TEA
• AVIATOR
• APHINITY
• monarchE
• NATALEE
• PALLAS

TARGET AUDIENCE

This educational activity was designed for community-based medical oncologists and other healthcare providers that treat and manage patients with breast cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options for patients with breast cancer

FACULTY

	Aditya Bardia, MD Director, Breast Cancer Research Associate Professor Harvard Medical School Attending Physician Massachusetts General Hospital Boston, Massachusetts
	Maryam Lustberg, MD, MPH Director, Center for Breast Cancer Smillow Cancer Hospital and Yale Cancer Center Chief, Breast Medical Oncology Yale Cancer Center New Haven, Connecticut
	Paolo Tarantino, MD Advanced Research Fellow Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Aditya Bardia, MD
Consultant: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi
Research Grants: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi

Maryam Lustberg, MD, MPH
Consultant: AstraZeneca, Eli Lily, Gilead, Novartis, Pfizer

Paolo Tarantino, MD
Consultant: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Novartis, Roche
Research Funding: AstraZeneca
Speaker: AstraZeneca, Daiichi Sankyo

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of January 9, 2024 through January 9, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 22, 2023
Expiration date: December 22, 2024
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

PROGRAM OVERVIEW

Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease that is typically treated with multimodal therapeutic approaches, which may include systemic therapies, radiotherapy, and surgery. Individualizing treatment strategies for patients with stage III NSCLC requires accurate clinical and pathological staging. The treatment journey of patients with stage III NSCLC has evolved rapidly over the last few years with improved staging approaches and approval of consolidation immunotherapy following concurrent chemoradiotherapy (cCRT).

Pretreatment multidisciplinary team discussion is crucial in defining the most optimal treatment approach for each patient. This activity will feature a multidisciplinary panel of three expert faculty discussing the current standard of care and the quickly moving science that is changing the treatment paradigm for patients with stage III unresectable NSCLC. The discussion will center around the treatment of a typical case and focus on optimal treatment selection, the challenges faced, and each faculty’s insight on their approach to treatment.

TARGET AUDIENCE

This educational activity was developed to meet the professional needs of medical, surgical, and radiation oncologists, along with other healthcare providers involved in the treatment and management of patients with lung cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Implement guideline recommended diagnostic and staging methodologies and utilize pretreatment multidisciplinary teams to individualize treatment plans for patients with unresectable stage III NSCLC
• Evaluate the efficacy and safety data of current and emerging therapeutic approaches for patients with unresectable stage III NSCLC
• Apply effective monitoring and management strategies for unique adverse events associated with chemoradiotherapy and consolidation immune checkpoint inhibitor treatment

FACULTY CO-CHAIRS

	Kristin A. Higgins, MD Professor and Vice Chair of Clinical Research Department of Radiation Oncology Winship Cancer Institute Emory University Atlanta, Georgia
	Onkar Khullar, MD, MSc, FACS  Associate Professor Department of Surgery Winship Cancer Institute Emory University Atlanta, Georgia
	Ticiana Leal, MD Associate Professor Department of Hematology/Oncology Director, Thoracic Medical Oncology Program Winship Cancer Institute Emory University Atlanta, Georgia

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Kristin A. Higgins, MD
Advisory Boards: AstraZeneca, Janssen Pharmaceuticals
Consultant: Picture Health
Funded Research: Jazz Pharmaceuticals

Onkar Khullar, MD, MSc, FACS, does not have any financial relationships or relationships to products or devices with ineligible companies.

Ticiana Leal, MD, does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 22, 2023 through December 22, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 21, 2023
Expiration date: December 21, 2024
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

PROGRAM OVERVIEW

Characterized by severe flares of painful, pruritic, pus-filled blisters, generalized pustular psoriasis (GPP) is a rare dermatologic disorder that many dermatologists have never seen…at least not that they realized. Historically thought of as a severe form of plaque psoriasis (PsO), recent insights into the pathogenesis of GPP show it to be a distinct immuno-inflammatory disease driven by overactivity of the IL-36 pathway.

Join GPP experts Dr. Mark Lebwohl and Dr. Boni Elewski to find out what dermatologists and other healthcare professionals need to know about the pathogenesis of GPP, the mechanism of action of IL-36 receptor antagonists, and how to recognize, diagnose, and manage patients with this inflammatory cutaneous disease.

TARGET AUDIENCE

This educational activity is designed for dermatologists and other healthcare professionals involved in the management of rare dermatologic conditions such as GPP, including primary care physicians, nurse practitioners, and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Identify patient characteristics, common comorbidities, and frequently observed triggers that should raise the index of suspicion for GPP and lead to a timelier diagnosis
• Describe the pathogenesis of GPP and the mechanism of action of interleukin-36 (IL-36) receptor antagonists
• Incorporate new and emerging IL-36 receptor inhibitors to treat and prevent GPP flares based on recent clinical trial findings
• Develop a multidisciplinary, patient-centric strategy to address the cutaneous and extracutaneous disease burden of GPP

FACULTY

Boni Elewski, MD Professor and Chair James Elder Endowed Professor of Graduate Medical Education Department of Dermatology Heersink School of Medicine University of Alabama Birmingham, Alabama

Mark Lebwohl, MD Dean for Clinical Therapeutics Icahn School of Medicine at Mount Sinai Professor and Chairman Emeritus Kimberly and Eric J. Waldman Department of Dermatology New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Boni Elewski, MD
Clinical research support: AbbVie, AnaptysBio, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, Janssen, Leo, Lilly, Novartis, Pfizer, UCB
Consulting fees: Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo, Lilly, Novartis, Ortho Dermatologics, UCB

Mark G. Lebwohl, MD
Research funds: AbbVie, Amgen, Arcutis Biotherapeutics, Inc., Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, UCB
Consulting fees: Almirall, AltruBio, Inc., AnaptysBio, Arcutis Biotherapeutics, Inc., AstraZeneca, Avotres Therapeutics, Brickell Biotech, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, EPI Health, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, Strata, Trevi, Verrica

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 21, 2023, through December 21, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 63% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 22, 2023
Expiration date: December 22, 2024
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

PROGRAM OVERVIEW

Effective treatments for schizophrenia have been available for decades, but by targeting only the dopamine neuropathway, currently available antipsychotics address only the positive symptoms — the voices, delusions, and hallucinations that are the recognizable hallmarks of the disease. However, two other symptom domains — negative and cognitive — can be just as debilitating, yet frequently go unrecognized and untreated. That’s likely because negative symptoms and cognitive impairment associated with schizophrenia (CIAS) are regulated by different, non-dopamine neurotransmitter pathways. Thus far, there have been no treatments to effectively address the flat affect and reduced motivation that are typical of negative symptoms or the poor memory and disorganized thinking that are characteristic of CIAS. Currently, though, several novel therapies are now in development to address these forgotten symptom domains of schizophrenia.

Join schizophrenia experts Dr. Daniel Javitt and Dr. Richard Keefe as they review the signs and traits of CIAS and negative symptoms and outline ways to address these forgotten domains of schizophrenia with current and emerging interventions.

TARGET AUDIENCE

This educational activity is designed for psychiatrists, psychologists, pharmacists, nurse practitioners, and physician assistants who specialize in psychiatry, and other clinicians and researchers who care for patients with schizophrenia.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Describe the unmet disease burden of CIAS
• Differentiate between two underrecognized and undermanaged domains in schizophrenia—negative symptoms and CIAS
• Incorporate an emerging treatment (when available) for patients for CIAS based on clinical trial efficacy, safety, and mechanism of action
• Identify potential benefits and limitations of digital therapeutics in the cognitive and negative and domains

FACULTY

Daniel C. Javitt, MD, PhD  Professor and Director, Division of Experimental Therapeutics Department of Psychiatry Columbia University Irving Medical Center New York, New York Director, Schizophrenia Research Nathan Kline Institute for Psychiatric Research Orangeburg, New York

Richard Keefe, PhD Emeritus Professor of Psychiatry Duke University Medical Center Durham, North Carolina

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Daniel C. Javitt, MD, PhD
Consultant: SK Life Science
Monitoring Board Member: Biogen
Internal Speaker: Boehringer Ingelheim
Major Shareholder: NRx Pharmaceuticals

Richard Keefe, PhD
Consultant: Biogen, Boehringer Ingelheim, Gedeon Richter, Karuna, Merck, Pangea Pharmaceuticals, Sirtsei Pharmaceuticals, WCG Clinical

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 22, 2023, through December 22, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 55% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 20, 2023
Expiration date: March 20, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

PROGRAM OVERVIEW

This activity will provide context and insight on the latest data in multiple myeloma and precursor conditions released at the recent meeting in San Diego, led by expert faculty, Dr. Ola Landgren. The following abstract will be covered:

• Updated Results from the Phase 3 PERSEUS Trial

TARGET AUDIENCE

This educational activity was designed for community-based medical oncologists and hematologists, as well as other healthcare providers that treat and manage patients with hematologic malignancies.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options
• Identify patients that could potentially benefit from referral to a clinical trial

FACULTY CHAIR

Ola Landgren, MD, PhD Chief of Myeloma Professor of Medicine Director, Slyvester Myeloma Institute University of Miami Miami, Florida

FACULTY DISCUSSANTS

	Ajay Nooka, MD, MPH Professor, Department of Hematology and Medical Oncology Director, Myeloma Program Medical Director, Winship Data and Technology Applications Shared Resource Associate Director of Clinical Research Winship Cancer Institute, Emory University School of Medicine Atlanta, Georgia
	Joshua Richter, MD Associate Professor of Medicine Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Ola Landgren, MD
Advisory Board: Adaptive Biotech, Amgen, Bristol Myers Squibb, Janssen, Pfizer
Grant Support: Amgen, Janssen, Karyopharm, Takeda

Ajay Nooka, MD, MPH
Consultant: Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Cellectar Biosciences, GlaxoSmithKline, Janssen, K36 Therapeutics, ONK Therapeutics, Pfizer, Sanofi, Takeda

Joshua Richter, MD
Advisory Boards: Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Consultant: Amgen, Array Biopharma, Bristol Myers Squibb , Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Speakers Bureaus: Adaptive Biotechnologies, Bristol Myers Squibb, Janssen, Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 20, 2023 through March 20, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 19, 2023
Expiration date: March 19, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This educational activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

PROGRAM OVERVIEW

Stage III non-small cell lung cancer (NSCLC) is a heterogenous disease that is typically treated with multimodal therapeutic approaches, which may include systemic therapies, radiotherapy, and surgery. Individualizing treatment strategies for patients with stage III NSCLC requires accurate clinical and pathological staging. The treatment journey of patients with stage III NSCLC has evolved rapidly over the last few years with improved staging approaches and approval of consolidation immunotherapy following concurrent chemoradiotherapy.

Pretreatment multidisciplinary team discussion is crucial in defining the most optimal treatment approach for each patient. This activity will feature Dr. Ticiana Leal summarizing a case focused on the optimal treatment of a patient diagnosed with stage III unresectable NSCLC.

TARGET AUDIENCE

This educational activity was developed to meet the professional needs of medical, surgical, and radiation oncologists, along with other healthcare providers involved in the treatment and management of patients with lung cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Evaluate the efficacy and safety data of current and emerging therapeutic approaches for patients with unresectable stage III NSCLC

FACULTY CHAIR

Ticiana Leal, MD Associate Professor Department of Hematology/Oncology Director, Thoracic Medical Oncology Program Winship Cancer Institute Emory University Atlanta, Georgia

FACULTY DISCUSSANTS

	Aakash Desai, MD Assistant Professor University of Alabama at Birmingham Birmingham, Alabama
	Kristin A. Higgins, MD Professor and Vice Chair of Clinical Research Department of Radiation Oncology Winship Cancer Institute Emory University Atlanta, Georgia

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Aakash Desai, MD
Consultant: Amgen, AstraZeneca, Foundation Medicine, Sanofi

Kristin A. Higgins, MD
Advisory Boards: AstraZeneca, Janssen Pharmaceuticals
Consultant: Picture Health
Funded Research: Jazz Pharmaceuticals

Ticiana Leal, MD, does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 19, 2023 through March 19, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 18, 2023
Expiration date: March 18, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharpe & Dohme, LLC.

PROGRAM OVERVIEW

This activity will provide context and insight on the latest data in breast cancer released at the recent meeting in San Antonio, led by expert faculty. The following abstracts will be covered:

• (GS03-03) Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial
• (GS03-06) Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial

TARGET AUDIENCE

This educational activity was designed for community-based medical oncologists and other healthcare providers that treat and manage patients with breast cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

•  Compare and contrast new and emerging therapies with established treatment options for patients with breast cancer

FACULTY CHAIR

Aditya Bardia, MD Director, Breast Cancer Research Associate Professor Harvard Medical School Attending Physician Massachusetts General Hospital Boston, Massachusetts

FACULTY DISCUSSANTS

	Adriana Kahn, MD Assistant Professor of Medicine, Medical Oncology Breast Oncology and Drug Development Yale School of Medicine New Haven, Connecticut
	Marija Sullivan, MD Hematology/Oncology Fellow MD Anderson Cancer Center Houston, Texas

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Aditya Bardia, MD
Consultant: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi
Research Grants: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi

Adriana Kahn, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

Marija Sullivan, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 18, 2023 through March 18, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 15, 2023
Expiration date: March 15, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharpe & Dohme, LLC.

PROGRAM OVERVIEW

This activity will provide context and insight on the latest data in breast cancer released at the recent meeting in San Antonio, led by expert faculty. The following abstract will be covered:

• Phase 3 CAPItello-291 Trial Insight

TARGET AUDIENCE

This educational activity was designed for community-based medical oncologists and other healthcare providers that treat and manage patients with breast cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

•  Compare and contrast new and emerging therapies with established treatment options for patients with breast cancer

FACULTY CHAIR

	Aditya Bardia, MD Director, Breast Cancer Research Associate Professor Harvard Medical School Attending Physician Massachusetts General Hospital Boston, Massachusetts
	Paolo Tarantino, MD Advanced Research Fellow Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts

FACULTY DISCUSSANTS

	Marija Sullivan, MD Hematology/Oncology Fellow MD Anderson Cancer Center Houston, Texas
	Megan Tesch, MD Instructor in Medicine Harvard Medical School Physician Dana-Farber Cancer Institute Breast Oncology Center

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Aditya Bardia, MD
Consultant: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi
Research Grants: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi

Marija Sullivan, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

Paolo Tarantino, MD
Consultant: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Novartis, Roche
Research Funding: AstraZeneca
Speaker: AstraZeneca, Daiichi Sankyo

Megan Tesch, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 15, 2023 through March 15, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 14, 2023
Expiration date: March 14, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharpe & Dohme, LLC.

PROGRAM OVERVIEW

This activity will provide context and insight on the latest data in breast cancer released at the recent meeting in San Antonio, led by expert faculty. The following abstract will be covered:

TARGET AUDIENCE

This educational activity was designed for community-based medical oncologists and other healthcare providers that treat and manage patients with breast cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

•  Compare and contrast new and emerging therapies with established treatment options for patients with breast cancer

FACULTY CHAIR

Maryam Lustberg, MD, MPH Director, Center for Breast Cancer Smillow Cancer Hospital and Yale Cancer Center Chief, Breast Medical Oncology Yale Cancer Center New Haven, Connecticut

FACULTY DISCUSSANTS

	Adriana Kahn, MD Assistant Professor of Medicine, Medical Oncology Breast Oncology and Drug Development Yale School of Medicine New Haven, Connecticut
	Dionisia Quiroga, DO, PhD Assistant Professor Department of Internal Medicine The Ohio State University Columbus, Ohio

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Adriana Kahn, MD has no real or apparent conflicts to disclose.

Maryam Lustberg, MD, MPH
Consultant: AstraZeneca, Eli Lily, Gilead, Novartis, Pfizer

Dionisia Quiroga, DO, PhD has no real or apparent conflicts to disclose.

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 14, 2023 through March 14, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 15, 2023
Expiration date: March 15, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

PROGRAM OVERVIEW

This activity will provide context and insight on the latest data in multiple myeloma and precursor conditions released at the recent meeting in San Diego, led by expert faculty, Dr. Saad Z. Usmani. The following abstract will be covered:

• Updated Results From the Phase 2 CARTITUDE-2 Trial

TARGET AUDIENCE

This educational activity was designed for community-based medical oncologists and hematologists, as well as other healthcare providers that treat and manage patients with hematologic malignancies.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options
• Identify patients that could potentially benefit from referral to a clinical trial

FACULTY CHAIR

Saad Usmani, MD, MBA, FACP, FRCP Chief of Myeloma Service Member, Memorial Sloan Kettering Cancer Center Attending Physician, Myeloma, Cellular Therapy and Adult BMT Professor, Weill Cornel Medical College – Cornell University New York, New York

FACULTY DISCUSSANTS

	Ajay Nooka, MD, MPH Professor, Department of Hematology and Medical Oncology Director, Myeloma Program Medical Director, Winship Data and Technology Applications Shared Resource Associate Director of Clinical Research Winship Cancer Institute, Emory University School of Medicine Atlanta, Georgia
	Joshua Richter, MD Associate Professor of Medicine Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Ajay Nooka, MD, MPH
Consultant: Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Cellectar Biosciences, GlaxoSmithKline, Janssen, K36 Therapeutics, ONK Therapeutics, Pfizer, Sanofi, Takeda

Joshua Richter, MD
Advisory Boards: Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Consultant: Amgen, Array Biopharma, Bristol Myers Squibb , Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Speakers Bureaus: Adaptive Biotechnologies, Bristol Myers Squibb, Janssen, Sanofi

Saad Usmani, MD, MBA, FACP, FRCP
Advisory Boards: AbbVie, Amgen, Bristol Myers Squibb , Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio
Consultant: AbbVie, Amgen, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio
Research Funding: Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 15, 2023 through March 15, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 13, 2023
Expiration date: March 13, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc, and Merck Sharpe & Dohme, LLC.

PROGRAM OVERVIEW

This activity will provide context and insight on the latest data in breast cancer released at the recent meeting in San Antonio, led by expert faculty. The following abstracts will be covered:

•  (PS08-01) Antibody-Drug Conjugates (ADCs) in Breast Cancer: Real World Analysis of Outcomes
• (GS02-01) Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01
• (PS17-03) Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive/HER2-negative advanced breast cancer: exploratory analysis of PFS by AKT pathway gene from the Phase 3 CAPItello-291 trial

TARGET AUDIENCE

This educational activity was designed for community-based medical oncologists and other healthcare providers that treat and manage patients with breast cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

•  Compare and contrast new and emerging therapies with established treatment options for patients with breast cancer

FACULTY CHAIR

Aditya Bardia, MD Director, Breast Cancer Research Associate Professor Harvard Medical School Attending Physician Massachusetts General Hospital Boston, Massachusetts

FACULTY DISCUSSANTS

	Marija Sullivan, MD Hematology/Oncology Fellow MD Anderson Cancer Center Houston, Texas
	Megan Tesch, MD Instructor in Medicine Harvard Medical School Physician Dana-Farber Cancer Institute Breast Oncology Center

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Aditya Bardia, MD
Consultant: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi
Research Grants: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi

Marija Sullivan, MD has no real or apparent conflicts to disclose.

Megan Tesch, MD has no real or apparent conflicts to disclose.

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 13, 2023 through March 13, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 6, 2023
Expiration date: December 6, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Merck Sharp & Dohme LLC.

PROGRAM OVERVIEW

This activity, Clinical Updates in Breast Cancer from Madrid, features expert faculty Dr. Aditya Bardia discussing the most important and clinically relevant data and framing it for integration into clinical practice.

The following abstracts will be covered:

• LBA21, KEYNOTE-756: Phase 3 Study of Neoadjuvant Pembrolizumab (Pembro) or Placebo (PBO) + Chemotherapy, Followed by Adjuvant Pembro or Pbo + Endocrine Therapy for Early-Stage, High-Risk ER+/HER2– Breast Cancer
• LBA20, A Randomized, Double-Blind Trial of Nivolumab (NIVO) vs Placebo (PBO) With Neoadjuvant Chemotherapy (NACT) Followed by Adjuvant Endocrine Therapy (ET) ± NIVO in Patients With High-Risk, ER+ HER2− Primary Breast Cancer
• LBA11, Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative (HR+/HER2–) Breast Cancer: Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial
• 377O, A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03
• 377O, A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03

TARGET AUDIENCE

This educational activity was designed for community-based medical oncologists and other healthcare providers that treat and manage patients with breast cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options

FACULTY CHAIR

Aditya Bardia, MD Director, Breast Cancer Research Associate Professor Harvard Medical School Attending Physician Massachusetts General Hospital Boston, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Aditya Bardia, MD
Consultant: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi
Research Grants: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 6, 2023 through December 6, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 8, 2023
Expiration date: June 8, 2024
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This educational activity is supported by an educational grant from GSK.

PROGRAM OVERVIEW

This educational initiative focuses on improving knowledge of respiratory syncytial virus (RSV) as a pathogen in older adults and the burden of the disease associated with the virus, RSV diagnosis and prevention strategies (including hygiene and vaccination), and data on the safety and efficacy of emerging vaccines. Additionally, expert faculty will provide insight on improving competence to incorporate vaccines into a multidisciplinary approach to healthy aging, with emphasis on the need to increase the rate of vaccination in older adults.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of physicians, physician assistants, nurse practitioners, respiratory therapists, and nurses involved in the management of older adults.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Discuss the burden, risk factors, and diagnosis of RSV in adults
• Review RSV prevention strategies, including hygiene and vaccination, and discuss the efficacy and safety of emerging vaccines for RSV
• Implement strategies to improve vaccine uptake in adults as part of a multidisciplinary approach to healthy aging

FACULTY

Antonio Anzueto, MD Professor of Medicine Pulmonary/Critical Care Medicine University of Texas Health Science Center at San Antonio San Antonio, Texas

Emily Toth, MPH, PhD Associate Professor of Epidemiology University of Michigan School of Public Health Ann Arbor, Michigan

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Antonio Anzueto, MD
Advisory Board: AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Pfizer, Verona Pharma
Consultant: AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Pfizer, Verona Pharma

Emily Toth Martin, MPH, PhD
Research Funds (Institution): Merck

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 8, 2023 through June 8, 2023 participants must:

• Read the learning objectives and faculty disclosures
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 60% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 30, 2023
Expiration date: November 30, 2024
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.
This CE activity for ANCC and AANP credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from GRAIL, LLC.

PROGRAM OVERVIEW

Early detection of cancer provides a critical opportunity to alter the course of disease, improving health measures and reducing overall cancer-related mortality. Nevertheless, significant shortcomings in early detection remain persistent, leaving many patients vulnerable to poor outcomes. While suboptimal screening practices are attributable to multiple factors, a key barrier is the limited number of cancer types for which screening methods are available, as well as inadequacies linked to health and sociodemographic disparities, and challenges in patient engagement related to preferences, values, and logistical concerns.

Nurse practitioners (NPs) and advanced practice nurses (APNs) play a critical role in health care delivery across a range of settings and are essential to bettering patient outcomes in many communities, particularly rural and underserved areas. Moreover, studies have shown that educational intervention for NPs and APNs on current cancer screening recommendations increases not only knowledge, but also actual rates of screening.

With this in mind, our program has been designed to provide NPs and APNs with the knowledge and skills needed to implement effective screening practices, including the use of novel technologies.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of nurse practitioners, advanced practice nurses, and physician assistants in primary care and specialty settings.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Describe the science that underlies multi-cancer screening tests and the rationale for their application
• Differentiate among new and emerging blood-based multi-cancer screening tests
• Employ strategies to reduce barriers to effective population-scale cancer screening, including health and sociodemographic disparities, and challenges in patient engagement
• Utilize cancer screening integration tools that increase patient engagement, improve patient outcomes, and promote continuity of care

FACULTY

Leigh Simpson, NP Internal Medicine Nurse Practitioner Intermountain Healthcare Sandy, Utah

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. and Global Education Group requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE/CME activity:

Leigh Simpson, NP has reported no financial relationships or relationships to products or devices with ineligible companies related to the content of this CE activity.

The Integrity Continuing Education, Inc. and the Global Education Group planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CE/CME credit for this activity. During the period of November 30, 2023 through November 30, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 75% or better and a completed activity evaluation form.

ACCREDITATION

Physician Continuing Education

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education, Inc. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour (which includes 0.0 hour(s) of pharmacology).

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.00 contact hour including 0.0 pharmacotherapeutic contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

For information about AANP or ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 30, 2023
Expiration date: November 30, 2024
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.
This CE activity for ANCC and AANP credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson and Merck Sharp & Dohme LLC.

PROGRAM OVERVIEW

An orphan disease with a poor prognosis, pulmonary arterial hypertension (PAH) presents in patients in the prime of their lives, inevitably causing right-heart failure and premature death, typically within 3-7 years.

Nurse Practitioners (NPs) are uniquely situated to help ensure earlier diagnosis and treatment initiation for improved outcomes in patients with PAH. This program is therefore designed to provide critical education to NPs and other clinicians on the frontline of cardiopulmonary care to address these shortcomings in practice through improved knowledge and competence of strategies for earlier identification and diagnosis of PAH and implementation of effective treatment regimens.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of nurse practitioners, advanced practice nurses, and physician assistants in primary care and specialty settings.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Delineate signs, symptoms, and risk factors that should raise the index of suspicion for PAH
• Identify patients who would benefit from referral to a cardiopulmonary specialist or PH/PAH specialty center to facilitate earlier diagnosis and treatment
• Design treatment plans that utilize current and emerging therapeutic regimens, including dual and triple combinations, and consider appropriate delivery mechanisms of individualized care of patients with PAH

FACULTY CHAIR

Martha Kingman, DNP, APRN, FNP-C Family Nurse Practitioner Pulmonary Hypertension Clinic University of Texas Southwestern Medical Center Dallas, Texas

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. and Global Education Group requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CE/CME activities:

Martha Kingman, DNP, APRN, FNP-C

Consultant/Advisor: Aerami, Aerovate, Bayer, Gossamer, Janssen, Liquidia, Merck, United Therapeutics

The Integrity Continuing Education, Inc. and the Global Education Group planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 30, 2023 through November 30, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 60% or better and a completed activity evaluation form.

ACCREDITATION

Physician Continuing Education

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education, Inc.. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour (which includes 0.0 hour(s) of pharmacology).

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hour including 0.0 pharmacotherapeutic contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

For information about AANP or ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 1, 2023
Expiration date: December 1, 2024
Estimated time to complete activity: 30 minutes

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Merck Sharp & Dohme LLC.

PROGRAM OVERVIEW

This activity, Clinical Updates in Non-Small Cell Lung Cancer from Madrid, features expert faculty Dr. Ticiana Leal discussing the most important and clinically relevant data and framing it for integration into clinical practice.

Abstracts included in this presentation include:

• LBA5 – Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From PAPILLON, a Randomized Phase 3 Global Study (Girad)
• LBA14 – Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial (Byoung Chul Cho )
• LBA15 – Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated Advanced NSCLC After Progression on Osimertinib: MARIPOSA-2, a Phase 3, Global, Randomized, Controlled Trial (Passaro)
• LBA12 – Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase 3 study TROPION-Lung01 (Lisberg)
• LBA56 – Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)

TARGET AUDIENCE

This educational activity was designed for community based medical oncologists and other healthcare providers that treat and manage patients with lung cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options

FACULTY CHAIR

Ticiana Leal, MD Associate Professor Department of Hematology/Oncology Director, Thoracic Medical Oncology Program Winship Cancer Institute Emory University Atlanta, Georgia

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Ticiana Leal, MD
Advisory board: AstraZeneca, Bayer, BeyondSpring, Blueprint, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genentech, InvisionFirst Lung, Janssen, Jazz, Merck, Takeda
Consultant: AstraZeneca, Boehringer Ingelheim, Genentech, Janssen, Jazz, Lilly

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 1, 2023 through December 1, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 27, 2023
Expiration date: November 27, 2024
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Merck Sharp & Dohme LLC.

PROGRAM OVERVIEW

This activity, Clinical Updates in Urothelial and Renal Cell Carcinoma from Madrid, features expert faculty Dr. Petros Grivas discussing the most important and clinically relevant data and framing it for integration into clinical practice. These insights are captured during the meeting and made available shortly thereafter to provide the latest information promptly for clinicians.

Abstracts included in the presentation include:

Urothelial Carcinoma

• LBA6 – EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC)
• 2359O – Phase 3 THOR Study: Results of Erdafitinib (erda) vs Pembrolizumab (pembro) in Pretreated Patients (pts) With Advanced or Metastatic Urothelial Cancer (mUC) With Select Fibroblast Growth Factor Receptor Alterations (FGFRalt)
• LBA102 – THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment
• LBA7 – Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial

Renal Cell Carcinoma

• LBA87 – Phase 2 LITESPARK-003 Study of Belzutifan in Combination With Cabozantinib for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
• LBA88 – Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase 3 LITESPARK-005 study
• 1881O – Safety and Efficacy of Two Doses of Belzutifan in Patients (pts) With Advanced RCC: Results of the Randomized Phase 2 LITESPARK-013 Study (Agarwal)

TARGET AUDIENCE

This educational activity was designed for community based medical oncologists and other healthcare providers that treat and manage patients with cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options
• Identify patients that could potentially benefit from referral to a clinical trial

FACULTY CHAIR

Petros Grivas, MD, PhD Professor, Department of Medicine Division of Hematology/Oncology Clinical Director, Genitourinary Cancers Program University of Washington Professor, Clinical Research Division Fred Hutchinson Cancer Center Seattle, Washington

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Petros Grivas, MD, PhD
Consulting: 4D Pharma PLC, Aadi Bioscience, AstraZeneca, Asieris Pharmaceuticals, Astellas Pharma, Bristol Myers Squibb, Boston Gene, CG Oncology, Dyania Health, Fresenius Kabi, G1 Therapeutics, Gilead, Guardant Health, ImmunityBio, Lucence Health, Infinity Pharmaceuticals, Janssen, Merck KGaA, MSD, Pfizer, PureTech, Roche, Seattle Genetics, Silverback Therapeutics, Strata Oncology, UroGen
Institutional research funding: Acrivon Therapeutics, ALX Oncology, Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, G1 Therapeutics, Gilead, GlaxoSmithKline, Merck KGaA, MSD, Mirati Therapeutics, Pfizer, QED Therapeutics

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 27, 2023 through November 27, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 16, 2023
Expiration date: February 16, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Merck Sharp & Dohme LLC.

PROGRAM OVERVIEW

There is an obvious need for treatment options for cervical cancer that provide durable and meaningful improvements in survival – approximately half of the women (48%) who complete first-line (1L) therapy for cervical cancer in community-based care subsequently receive second-line therapy, with a median treatment-free interval of only 2.1 months. However, the treatment landscape is changing, and recent data has shown a survival benefit with the addition of immune checkpoint inhibitors to 1L chemotherapy, which may improve the outlook for many women with cervical cancer. This activity features a case-based discussion with expert faculty that will provide insight on the practical application of this new data.

In this Twitter-based Clinical Brief, Drs. Elenora Teplinsky and Gregg Nelson will discuss approaches to treatment and adverse event management for women with cervical cancer.

TARGET AUDIENCE

This educational activity was designed for medical and gynecologic oncologists who treat gynecologic malignancies.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Apply recommendations and clinical trial evidence to treatment and adverse event management for women with cervical cancer

FACULTY CHAIR

Eleonora Teplinsky, MD Head, Breast Medical Oncology Clinical Assistant Professor of Medicine Icahn School of Medicine at Mount Sinai Paramus, New Jersey

FACULTY DISCUSSANT

Gregg Nelson, MD, PhD, FRCSC Professor and Chief of Gynecologic Oncology Department of Obstetrics & Gynecology Cumming School of Medicine University of Calgary Calgary, Alberta

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Gregg Nelson, MD, PhD, FRCSC does not have any financial relationships or relationships to products or devices with ineligible companies.

Elenora Teplinsky, MD
Advisory Board: AstraZeneca
Medical Advisor: FloHealth, Sermo

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 16, 2023 through February 16, 2024 participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 8, 2023
Expiration date: November 8, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Merck Sharp & Dohme LLC.

PROGRAM OVERVIEW

The incidence of cervical cancer may be decreasing due to widespread screening and prevention efforts and improved access to care, but racial and ethnic disparities remain in both cervical cancer incidence and mortality, with higher rates among Black and Hispanic women than White women. Further, there is an obvious need for treatment options that provide durable and meaningful improvements in survival – approximately half of the women (48%) who complete first-line (1L) therapy for cervical cancer in community-based care subsequently receive second-line therapy, with a median treatment-free interval of only 2.1 months. However, the treatment landscape is changing, and recent data has shown a survival benefit with the addition of immune checkpoint inhibitors to 1L chemotherapy, which may improve the outlook for many women with cervical cancer.

This In the Clinic activity features a case-based discussion with expert faculty that will provide insight on the practical application of this new data.

TARGET AUDIENCE

This educational activity was designed for medical and gynecologic oncologists who treat gynecologic malignancies.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Apply recommendations and clinical trial evidence to treatment and adverse event management for women with cervical cancer
• Identify the effects of and strategies to overcome disparities in care

FACULTY

Martina C. Murphy, MD    Associate Professor of Medicine Program Director, Hematology/Oncology Fellowship University of Florida Assistant Director, Clinical Research Education & Professional Development Medical Director, Communication Strategies & Digital Innovation University of Florida Health Cancer Center Gainesville, Florida

CASE DEVELOPMENT FACULTY

Megan Hutchcraft, MD  Gynecologic Oncologist Carle Cancer Institute Assistant Clinical Professor Carle Illinois College of Medicine University of Illinois at Urbana-Champaign Champaign, Illinois

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Megan Hutchcraft, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

Martina C. Murphy, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 8, 2023 through November 8, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 15, 2023
Expiration date: March 15, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This program is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This educational activity is supported by an educational grant from GSK.

PROGRAM OVERVIEW

Anemia occurs in nearly all patients with myelofibrosis and is associated with poor prognosis, worse survival, and reduced quality of life. Patients with anemia will often require blood transfusion, though a subset will derive temporary benefit from androgens, corticosteroids, immunomodulators, or erythropoiesis stimulating agents. Since the majority of patients will not have a prolonged response to these agents, new therapies are needed and may soon enter clinical practice.

Treating and managing the complex etiology of myelofibrosis-associated anemia is challenging, especially for clinicians who practice outside of specialty/academic centers and do not regularly treat patients with myelofibrosis. This Twitter-based Clinical Brief activity will discuss emerging treatment options for patients with myelofibrosis.

TARGET AUDIENCE

This activity has been developed to meet the professional needs of medical oncologists and hematologists, as well as other healthcare professionals who treat and manage patients with hematologic malignancies.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Select the best treatment based on patient and disease characteristics

FACULTY CO-CHAIRS

	Luke Fletcher, MD Hematology/Oncologist Willamette Valley Cancer Institute Eugene, Oregon Clinical Researcher, Executive Committee Member Department of Malignant Hematology-Leukemia Sarah Cannon Research Institute Nashville, Tennessee
	Aaron T. Gerds, MD, MS Associate Professor of Medicine Hematology & Medical Oncology Deputy Director for Clinical Research Cleveland Clinic Taussig Cancer Institute Medical Director, Case Comprehensive Cancer Center Clinical Research Office Cleveland, Ohio

FACULTY DISCUSSANTS

	Andrew Kuykendall, MD Assistant Professor Oncologic Sciences University of South Florida Assistant Member, Moffit Cancer Center Department of Malignant Hematology Tampa, Florida
	Raajit Rampal, MD, PhD Director, Center for Hematologic Malignancies Director, Myeloproliferative Neoplasms Program Memorial Sloan Kettering Cancer Center New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Luke Fletcher, MD
Consultant: Genzyme, Morphosys, Novartis, PharmaEssentia, Sanofi, Servier
Speaker: CTI Biopharma

Aaron T. Gerds, MD, MS
Consultant: AbbVie, Bristol Myers Squibb, CTI Biopharma, GSK/Sierra Oncology, Imago, Morphosys, Novartis, PharmaEssentia

Andrew Kyukendall, MD
Consultant: AbbVie, GSK
Honoraria: Bristol Myers Squibb, CTI Biopharma, Incyte, Morphosys
Research support: Bristol Myers Squibb, Janssen, Morphosys

Raajit Rampal, MD, PhD
Consultant: AbbVie, Blueprint, Bristol Myers Squibb, Cogent, Constellation, CTI Biopharma, Galecto, GSK, Incyte, Kartos, Karyopharm, Novartis, PharmaEssentia, Sumitomo Dainippon Pharma Oncology, Servier, Stemline, Zentalis

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 15, 2023 through March 15, 2024 participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: October 27, 2023
Expiration date: January 27, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Merck Sharp & Dohme LLC.

PROGRAM OVERVIEW

International society meetings are a primary source of new data in oncology. Keeping up to date with the fast pace of oncology, sorting through thousands of abstracts, and deciding what is or is not ready for the clinic are daunting tasks. This activity, Clinical Updates in Urothelial Carcinoma from Madrid, features expert faculty Dr. Petros Grivas discussing the most important and clinically relevant data and framing it for integration into clinical practice. These insights are captured during the meeting and made available shortly thereafter to provide the latest information promptly for clinicians.

This Twitter-based activity will focus on first-line therapy for patients with locally advanced/metastatic urothelial carcinoma, irrespective of cisplatin eligibility.

TARGET AUDIENCE

This educational activity was designed for community based medical oncologists and other healthcare providers that treat and manage patients with cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options

FACULTY CHAIR

Petros Grivas, MD, PhD Professor, Department of Medicine Division of Hematology/Oncology Clinical Director, Genitourinary Cancers Program University of Washington Professor, Clinical Research Division Fred Hutchinson Cancer Center Seattle, WA

FACULTY DISCUSSANT

Jonathan Anker, MD, PhD Clinical and Research Fellow Department of Hematology and Medical Oncology The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Hospital New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Jonathan Anker, MD, PhD does not have any financial relationships or relationships to products or devices with ineligible companies.

Petros Grivas, MD, PhD
Consulting: 4D Pharma PLC, Aadi Bioscience, AstraZeneca, Asieris Pharmaceuticals, Astellas Pharma, Bristol Myers Squibb, Boston Gene, CG Oncology, Dyania Health, Fresenius Kabi, G1 Therapeutics, Gilead, Guardant Health, ImmunityBio, Lucence Health, Infinity Pharmaceuticals, Janssen, Merck KGaA, MSD, Pfizer, PureTech, Roche, Seattle Genetics, Silverback Therapeutics, Strata Oncology, UroGen
Institutional research funding: Acrivon Therapeutics, ALX Oncology, Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, G1 Therapeutics, Gilead, GlaxoSmithKline, Merck KGaA, MSD, Mirati Therapeutics, Pfizer, QED Therapeutics

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 27, 2023 through January 27, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 2, 2023
Expiration date: February 2, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Merck Sharp & Dohme LLC.

PROGRAM OVERVIEW

International society meetings are a primary source of new data in oncology. Keeping up to date with the fast pace of oncology, sorting through thousands of abstracts, and deciding what is or is not ready for the clinic are daunting tasks. This activity, Clinical Updates in Breast Cancer from Madrid, features expert faculty Dr. Aditya Bardia discussing the most important and clinically relevant data and framing it for integration into clinical practice. These insights are captured during the meeting and made available shortly thereafter to provide the latest information promptly for clinicians.

This Twitter-based activity will focus on neoadjuvant immune checkpoint inhibitor + chemotherapy for high-risk ER+/HER2- breast cancer.

TARGET AUDIENCE

This educational activity was designed for community based medical oncologists and other healthcare providers that treat and manage patients with cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options

FACULTY CHAIR

Aditya Bardia, MD Director, Breast Cancer Research Associate Professor Harvard Medical School Attending Physician Massachusetts General Hospital Boston, Massachusetts

FACULTY DISCUSSANT

Megan Tesch, MD Instructor in Medicine Harvard Medical School Physician Dana-Farber Cancer Institute Breast Oncology Center Boston, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Aditya Bardia, MD
Consultant: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi
Research Grants: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi

Megan Tesch, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 2, 2023 through February 2, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 9, 2023
Expiration date: February 9, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Incyte Corporation.

PROGRAM OVERVIEW

“If you’ve seen one patient with vitiligo…you’ve seen one patient with vitiligo,” vitiligo expert Dr. David Rosmarin is fond of saying. This relatively common dermatologic disorder can present in a wide variety of ways and its impact on patients’ quality of life can be profound yet highly individual.

In this Twitter-based Clinical Brief, David Rosmarin, MD, Colleen Cotton, MD, FAAD, and Seemal Desai, MD, FAAD will discuss switching therapies to align with patients’ vitiligo treatment goals.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of dermatologists, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage patients with vitiligo.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Recall clinical trial data for new and emerging therapies for vitiligo

FACULTY CHAIR

David Rosmarin, MD Chair of Dermatology Kampen-Norins Scholar Indiana University School of Medicine Indianapolis, Indiana

FACULTY DISCUSSANTS

	Colleen Cotton, MD, FAAD Assistant Professor of Dermatology and Pediatrics George Washington School of Medicine and Health Sciences Attending Physician Division of Dermatology, Children’s National Hospital Washington, District of Columbia
	Seemal Desai, MD, FAAD Founder and Medical Director Innovative Dermatology Clinical Assistant Professor Department of Dermatology The University of Texas Southwestern Dallas, Texas

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Colleen Cotton, MD, FAAD
Advisor: Avita, Bristol Myers Squibb, Janssen Biotech, LEO Pharma
Consultant: Pierre Fabre
Salary Support: Eli Lilly, Regeneron, Target RWA
Research: AbbVie, Arcutis Biotherapeutics

Seemal Desai, MD, FAAD
Advisory Board: Foundation for Research & Education of Dermatology
Board of Directors: Global Vitiligo Foundation, International Society of Dermatology, Women’s Derm Society
Consultant: AbbVie, Allergan, Inc., Almirall, Amgen, Apogee Therapeutics, Avita, Ballature Beauty, Beiersdorf, Inc., Bristol Myers Squibb, Candela Corporation, Cassiopea S.p.A., Castle Biosciences, Cutera, Inc., Dermavant Sciences, Dermira, Eli Lilly and Company, EPI Health, Ferndale Laboratories, Inc., Foamix, Galderma Laboratories, LP, Gore Range Capital, Hyphens Pharma, Incyte Corporation, Janssen Pharmaceuticals, Inc., Johnson and Johnson, Leo Pharma Inc., L’Oreal USA Inc., Lyceum Health, Ortho Dermatologics, Pfizer Inc., Revision Skincare, Sanofi/Regeneron, Scientis, Skin Science Advisors, UCB, Verrica Pharmaceuticals Inc., VYNE Therapeutics
Investigator: AOBiome, LLC., Atacama Therapeutics, Dermavant Sciences, Incyte Corporation, SkinMedica, Inc.
Other: Medscape, National Psoriasis Foundation, PDH Holdings LLC
Founder: Illuminate Skin Care LLC
Speaker: AbbVie, Dermira, Galderma Laboratories, LP., Pfizer Inc.
Stockholder: Gore Range Capital

David Rosmarin, MD
Consultant: AbbVie, Abcuro, AltruBio, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Incyte, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Recludix, Regeneron, Revolo Biotherapeutics, Sanofi, Sun Pharma, UCB, Viela Bio
Research: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron
Speaker: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Dermavant, Incyte, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 9, 2023 through February 9, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 1, 2023
Expiration date: February 1, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Merck Sharp & Dohme LLC.

PROGRAM OVERVIEW

International society meetings are a primary source of new data in oncology. Keeping up to date with the fast pace of oncology, sorting through thousands of abstracts, and deciding what is or is not ready for the clinic are daunting tasks. This activity, Clinical Updates in Non-Small Cell Lung Cancer from Madrid, features expert faculty Dr. Ticiana Leal discussing the most important and clinically relevant data and framing it for integration into clinical practice. These insights are captured during the meeting and made available shortly thereafter to provide the latest information promptly for clinicians.

This Twitter-based activity will focus on the new first-line standard of care for epidermal growth factor receptor (EGFR) exon 20 insertion-mutated advanced non-small cell lung cancer.

TARGET AUDIENCE

This educational activity was designed for community based medical oncologists and other healthcare providers that treat and manage patients with cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options

FACULTY CHAIR

Ticiana Leal, MD Associate Professor Department of Hematology/Oncology Director, Thoracic Medical Oncology Program Winship Cancer Institute Emory University Atlanta, Georgia

FACULTY DISCUSSANT

Aakash Desai, MD, MPH Assistant Professor University of Alabama at Birmingham Birmingham, Alabama

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Ticiana Leal, MD
Advisory board: AstraZeneca, Bayer, BeyondSpring, Blueprint, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genentech, InvisionFirst Lung, Janssen, Jazz, Merck, Takeda
Consultant: AstraZeneca, Boehringer Ingelheim, Genentech, Janssen, Jazz, Lilly

Aakash Desai, MD, MPH
Consultant: Amgen, AstraZeneca, Foundation Medicine, Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 1, 2023 through February 1, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 1, 2023
Expiration date: March 1, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This program is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This educational activity is supported by an educational grant from GSK.

PROGRAM OVERVIEW

Anemia occurs in nearly all patients with myelofibrosis and is associated with poor prognosis, worse survival, and reduced quality of life. Patients with anemia will often require blood transfusion, though a subset will derive temporary benefit from androgens, corticosteroids, immunomodulators, or erythropoiesis stimulating agents. Since the majority of patients will not have a prolonged response to these agents, new therapies are needed and may soon enter clinical practice.

Treating and managing the complex etiology of myelofibrosis-associated anemia is challenging, especially for clinicians who practice outside of specialty/academic centers and do not regularly treat patients with myelofibrosis. This Twitter-based Clinical Brief activity will discuss the unmet needs in patients with myelofibrosis, with a focus on prognostic factors and how they impact treatment choices.

TARGET AUDIENCE

This activity has been developed to meet the professional needs of medical oncologists and hematologists, as well as other healthcare professionals who treat and manage patients with hematologic malignancies.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Assess and apply prognostic scoring in the treatment planning process

FACULTY CO-CHAIRS

	Luke Fletcher, MD Hematology/Oncologist Willamette Valley Cancer Institute Eugene, Oregon Clinical Researcher, Executive Committee Member Department of Malignant Hematology-Leukemia Sarah Cannon Research Institute Nashville, Tennessee
	Aaron T. Gerds, MD, MS Associate Professor of Medicine Hematology & Medical Oncology Deputy Director for Clinical Research Cleveland Clinic Taussig Cancer Institute Medical Director, Case Comprehensive Cancer Center Clinical Research Office Cleveland, Ohio

FACULTY DISCUSSANTS

	Talha Badar, MD, MBBS Department of Hematology and Oncology Mayo Clinic Jacksonville, Florida
	Vikas Gupta, MD, FRCP, FRCPath Professor, Department of Medicine Department of Medical Oncology and Hematology University of Toronto Site Group Lead, Leukemia/MPN Programs Princess Margaret Cancer Centre Ontario, Canada

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Talha Badar, MD, MBBS
Advisory Boards: Pfizer, Takeda

Luke Fletcher, MD
Consultant: Genzyme, Morphosys, Novartis, PharmaEssentia, Sanofi, Servier
Speaker: CTI Biopharma

Aaron T. Gerds, MD, MS
Consultant: AbbVie, Bristol Myers Squibb/Celgene, CTI Biopharma, GSK/Sierra Oncology, Imago, Morphosys, Novartis, PharmaEssentia

Vikas Gupta, MD, FRCP, FRCPath
Consultant: AbbVie, Bristol Myers Squibb/Celgene, CTI Biopharma, Incyte, Morphosys, Novartis, Sierra Oncology, Takeda
Research Support: Novartis
Scientific Advisory Board: AbbVie, Bristol Myers Squibb/Celgene, CTI Biopharma, Incyte, Morphosys, Novartis, Sierra Oncology, Takeda

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 1, 2023 through March 1, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: October 31, 2023
Expiration date: April 30, 2024
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc., and Sanofi.

PROGRAM OVERVIEW

Chronic rhinosinusitis (CRS) is among the most prevalent and expensive chronic disorders in the US. According to the Centers for Disease Control and Prevention, 28.9 million adults (11.6%) have CRS, and at least one economic analysis ranks the disease among the top 10 most costly conditions. Among patients with CRS, an estimated 25%–30% have concurrent nasal polyps (CRSwNP). CRSwNP is most commonly observed in patients between 40 and 60 years of age, and while polyps are more common in men, women are more likely to have severe disease, comorbid asthma, and aspirin-exacerbated respiratory disease. Compared to their counterparts without polyps (CRSsNP), patients with CRSwNP carry a much higher disease burden, greater risk for comorbidities, the need for functional endoscopic sinus surgery (ESS), repeat revision surgeries, and dependence on oral corticosteroids (OCS).

This activity will improve patient care through improved ability to assess disease severity and burden, selection of patients for surgical or biologic treatment options, and evidence on comparative safety and efficacy and real-world data of available treatments for CRSwNP. Listen in as Drs. Lee, Peters, and Platt present a brief lecture, then participate in an interactive poster session where they dive deeper into these topics.

TARGET AUDIENCE

This activity addresses the needs of otolaryngic allergists, physicians, physician assistants, and nurse practitioners involved in the management of patients with CRSwNP.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Apply evidence-based guidance to assess the severity and QOL impact of CRSwNP
• Evaluate clinical trial data on the efficacy and safety of biologics and surgical options for patients with CRSwNP
• Incorporate current guidelines and expert recommendations into the positioning of biologic therapy, sinus surgery, and OCS for the treatment of patients with CRSwNP

FACULTY

	Stella Lee, MD Section Chief Rhinology Brigham and Women’s Hospital Harvard Medical School Weston, Massachusetts
	Anju T. Peters, MD Professor of Medicine Director of Clinical Research Division of Allergy/Immunology and Otolaryngology Northwestern University Feinberg School of Medicine Chicago, Illinois
	Michael Platt, MD, MSc Associate Professor and Residency Director Director of Rhinology and Endoscopic Skull Base Surgery Department of Otolaryngology- Head and Neck Surgery Chobanian and Avedesian School of Medicine Boston University Boston, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Stella Lee, MD
Advisory Board: AstraZeneca, Genentech, GSK, Lyra Therapeutics, OptiNose, Sanofi Regeneron

Anju Peters, MD
Advisory Board: AstraZeneca, GSK, Merck, Sanofi Regeneron
Consulting: OptiNose
Research: AstraZeneca, Merck, Sanofi Regeneron

Michael Platt, MD, MSc
Consulting: GI Reviewers, LLC. Independent reader for CRS biologics studies

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 31, 2023 through April 30, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 75% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: October 30, 2023
Expiration date: January 30, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Merck Sharp & Dohme LLC.

PROGRAM OVERVIEW

International society meetings are a primary source of new data in oncology. Keeping up to date with the fast pace of oncology, sorting through thousands of abstracts, and deciding what is or is not ready for the clinic are daunting tasks. This activity, Clinical Updates in Renal Cell Carcinoma from Madrid, features expert faculty Dr. Petros Grivas discussing the most important and clinically relevant data and framing it for integration into clinical practice. These insights are captured during the meeting and made available shortly thereafter to provide the latest information promptly for clinicians.

This Twitter-based activity will focus on post-immunotherapy tyrosine kinase inhibitor (TKI) therapy in renal cell carcinoma.

TARGET AUDIENCE

This educational activity was designed for community based medical oncologists and other healthcare providers that treat and manage patients with cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options

FACULTY CHAIR

Petros Grivas, MD, PhD Professor, Department of Medicine Division of Hematology/Oncology Clinical Director, Genitourinary Cancers Program University of Washington Professor, Clinical Research Division Fred Hutchinson Cancer Center Seattle, Washington

FACULTY DISCUSSANT

Jonathan Anker, MD, PhD Clinical and Research Fellow Department of Hematology and Medical Oncology The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Hospital New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Jonathan Anker, MD, PhD does not have any financial relationships or relationships to products or devices with ineligible companies.

Petros Grivas, MD, PhD
Consulting: 4D Pharma PLC, Aadi Bioscience, AstraZeneca, Asieris Pharmaceuticals, Astellas Pharma, Bristol Myers Squibb, Boston Gene, CG Oncology, Dyania Health, Fresenius Kabi, G1 Therapeutics, Gilead, Guardant Health, ImmunityBio, Lucence Health, Infinity Pharmaceuticals, Janssen, Merck KGaA, MSD, Pfizer, PureTech, Roche, Seattle Genetics, Silverback Therapeutics, Strata Oncology, UroGen
Institutional research funding: Acrivon Therapeutics, ALX Oncology, Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, G1 Therapeutics, Gilead, GlaxoSmithKline, Merck KGaA, MSD, Mirati Therapeutics, Pfizer, QED Therapeutics

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 30, 2023 through January 30, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 29, 2023
Expiration date: March 29, 2024
Estimated time to complete activity: 30 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

PROGRAM OVERVIEW

Homozygous familial hypercholesterolemia (HoFH) is a genetic disorder characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C), leading to premature cardiovascular disease. Affected individuals are typically less responsive or unresponsive to standard lipid-lowering therapies (ie, statins and PCSK9 inhibitors) and may benefit from treatments with alternative mechanisms of action, such as the recently FDA-approved ANGPTL3 inhibitor evinacumab. With this in mind, this program has been designed to educate clinicians about the prevalence of HoFH, the importance of HoFH screening, and the benefits and limitations of current therapies for lipid management in patients with the disease. The nationally-recognized expert faculty in HoFH presenting this activity will provide practical advice geared for an audience of primary care providers regarding the best strategies to improve patient access to newer lipid-lowering therapies.

TARGET AUDIENCE

This educational activity has been designed for US internal medicine physicians, nurse practitioners, and physician assistants involved in the identification, diagnosis, and management of patients with HoFH.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Contrast the estimated prevalence versus the number of patients diagnosed with familial hypercholesterolemia (FH)
• Apply knowledge of cardinal symptoms and strategies for early identification of HoFH
• Employ cascade screening to ensure case identification in first degree relatives of patients with HoFH
• Discuss the role of low-density lipoprotein receptor-independent treatment strategies for patients with HoFH

FACULTY

Mary P. McGowan, MD Assistant Professor of Medicine Geisel School of Medicine at Dartmouth Co-Director, Lipid Clinic Dartmouth Hitchcock Medical Center Lebanon, New Hampshire

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Mary P. McGowan, MD
Consultant: Novartis
Speaker: Abbott

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 29, 2023 through March 29, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 70% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: October 26, 2023
Expiration date: January 26, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Incyte Corporation.

PROGRAM OVERVIEW

“If you’ve seen one patient with vitiligo…you’ve seen one patient with vitiligo,” vitiligo expert Dr. David Rosmarin is fond of saying. This relatively common dermatologic disorder can present in a wide variety of ways and its impact on patients’ quality of life can be profound yet highly individual.

In this Twitter-based Clinical Brief, David Rosmarin, MD, Colleen Cotton, MD, FAAD, and Seemal Desai, MD, FAAD will discuss therapy options available to younger patients who have been diagnosed with vitiligo.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of dermatologists, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage patients with vitiligo.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Recall clinical trial data for new and emerging therapies for vitiligo

FACULTY CHAIR

David Rosmarin, MD Chair of Dermatology Kampen-Norins Scholar Indiana University School of Medicine Indianapolis, Indiana

FACULTY DISCUSSANTS

	Colleen Cotton, MD, FAAD Assistant Professor of Dermatology and Pediatrics George Washington School of Medicine and Health Sciences Attending Physician Division of Dermatology, Children’s National Hospital Washington, District of Columbia
	Seemal Desai, MD, FAAD Founder and Medical Director Innovative Dermatology Clinical Assistant Professor Department of Dermatology The University of Texas Southwestern Dallas, Texas

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Colleen Cotton, MD, FAAD
Advisor: Avita, Bristol Myers Squibb, Janssen Biotech, LEO Pharma
Consultant: Pierre Fabre
Salary Support: Eli Lilly, Regeneron, Target RWA
Research: AbbVie, Arcutis Biotherapeutics

Seemal Desai, MD, FAAD
Advisory Board: Foundation for Research & Education of Dermatology
Board of Directors: Global Vitiligo Foundation, International Society of Dermatology, Women’s Derm Society
Consultant: AbbVie, Allergan, Inc., Almirall, Amgen, Apogee Therapeutics, Avita, Ballature Beauty, Beiersdorf, Inc., Bristol Myers Squibb, Candela Corporation, Cassiopea S.p.A., Castle Biosciences, Cutera, Inc., Dermavant Sciences, Dermira, Eli Lilly and Company, EPI Health, Ferndale Laboratories, Inc., Foamix, Galderma Laboratories, LP, Gore Range Capital, Hyphens Pharma, Incyte Corporation, Janssen Pharmaceuticals, Inc., Johnson and Johnson, Leo Pharma Inc., L’Oreal USA Inc., Lyceum Health, Ortho Dermatologics, Pfizer Inc., Revision Skincare, Sanofi/Regeneron, Scientis, Skin Science Advisors, UCB, Verrica Pharmaceuticals Inc., VYNE Therapeutics
Investigator: AOBiome, LLC., Atacama Therapeutics, Dermavant Sciences, Incyte Corporation, SkinMedica, Inc.
Other: Medscape, National Psoriasis Foundation, PDH Holdings LLC
Founder: Illuminate Skin Care LLC
Speaker: AbbVie, Dermira, Galderma Laboratories, LP., Pfizer Inc.
Stockholder: Gore Range Capital

David Rosmarin, MD
Consultant: AbbVie, Abcuro, AltruBio, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Incyte, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Recludix, Regeneron, Revolo Biotherapeutics, Sanofi, Sun Pharma, UCB, Viela Bio
Research: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron
Speaker: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Dermavant, Incyte, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 26, 2023 through January 26, 2023, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION